Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | BTN3A1 | O00481 | 6/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.34 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | ENO1 | P06733 | 1/20 | 0.33 |
| ▸ | ELANE | P08246 | 3/20 | 0.31 |
| ▸ | TK1 | P04183 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681950 | 0.87 | PRKCA (0.46) | PRKCABTN3A1ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL4482845 | 0.83 | GAA (0.46) | PRKCABTN3A1ALDH1A1CYP4F2CYP4A11 | |
| Bis(Pivaloyloxymethyl) Succinate SCHEMBL3123390 | 0.83 | PRKCA (0.41) | PRKCABTN3A1ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL8893353 | 0.81 | PRKCA (0.39) | PRKCABTN3A1ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL7338739 | 0.81 | NAAA (0.40) | PRKCABTN3A1ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL434232 | 0.80 | PRKCA (0.42) | PRKCABTN3A1ALDH1A1CYP4F2CYP4A11 | |
| SCHEMBL12842576 | 0.79 | PRKCA (0.38) | PRKCABTN3A1ALDH1A1POLBGAA | |
| SCHEMBL3835100 | 0.79 | DGKA (0.43) | PRKCABTN3A1ALDH1A1ELANE | |
| SCHEMBL3277597 | 0.79 | ADRA2A (0.33) | ALDH1A1GAA | |
| SCHEMBL8716409 | 0.78 | PRKCA (0.41) | PRKCABTN3A1ALDH1A1CYP4F2CYP4A11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | PELOTON THERAPEUTICS, INC. (US) | 2025-06-17 | — | — | US | disclosed |
| EP-3810109-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING CD73 | PELOTON THERAPEUTICS INC (US) | 2024-08-07 | — | — | EP | disclosed |
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | PELOTON THERAPEUTICS, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| EP-3810109-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | Peloton Therapeutics, Inc. (US) | 2021-04-28 | — | — | EP | disclosed |
| US-20160095831-A1 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-04-07 | — | — | US | disclosed |
| US-5643878-A | TREATMENT OF RETROVIRAL DISEASES LIKE AIDS | CIBA-GEIGY CORPORATION (US) | 1997-07-01 | — | — | US | disclosed |
| EP-0618222-A2 | Dipeptid derivatives of 5-amino-4-hydroxy-hexanoic acid | CIBA-GEIGY AG (CH) | 1994-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210253614-A1 | COMPOSITIONS AND METHODS FOR INHIBITING CD73 | ENTPD5, NT5E, ENTPD1 | PRKCA 1250/4885BTN3A1 1748/4885ALDH1A1 868/4885 |
| US-20160095831-A1 | USE OF HYDROGEN SULFIDE SYNTHESIS INHIBITORS FOR CANCER THERAPY | CBS, CTH, HCCS | PRKCA 1178/4885BTN3A1 4020/4885ALDH1A1 919/4885 |
| US-12331068-B2 | Compositions and methods for inhibiting CD73 | ENTPD5, NT5E, ENTPD1 | PRKCA 1250/4885BTN3A1 1748/4885ALDH1A1 868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.